BioCentury
ARTICLE | Company News

Acetylon, Celgene deal

August 15, 2016 7:00 AM UTC

Celgene revealed in a regulatory filing that it did not exercise its option to acquire Acetylon. Celgene allowed the option to expire in May. It paid $100 million up front to acquire the option in 201...